BeNeLuxBelgiumNetherlandsLuxembourg

ThromboGenics sees eye drug on home stretch to approval

22.08.2011

Leuven – ThromboGenics NV presented promising results of its Ocriplasmin Phase III clinical program at the Annual Meeting of the American Society of Retina Specialists (ASRS). „We remain on track to make regulatory filings for this novel compound in Europe and the U.S. by the year-end”, CEO Patrik de Haes said. Ocriplasmin is a novel pharmacological agent being investigated for the treatment of symptomatic vitreomacular adhesion (VMA) including macular holes. Symptomatic VMA is a condition when the vitreous gel adheres in an abnormally strong manner to the retina. VMA can lead to loss or distortion of visual acuity. In 2010, Ocriplasmin completed two Phase III trials involving a total of 652 patients in Europe and the U.S. New data now presented confirms that a single injection of ocriplasmin resolved VMA and the visual symptoms associated with it in 29.8% of VMT patients, compared with 7.7% of patients on placebo. After 6 months Ocriplasmin appears to lower the incidence of retinal tears or detachments, seen in just 1.7% of patients, compared with 4.3% on placebo. ThromboGenics says that there are approximately 500,000 patients in the U.S. and major markets of the EU who would benefit from ocriplasmin if it were approved for symptomatic VMA including macular holes.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1983

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/thrombogenics-sees-eye-drug-on-home-stretch-to-approval.html

Product of the week

Products

Events

All Events

Current issue

All issues